Ripretinib drug donation policy

Ripretinib is a novel switch-controlled TKI designed to inhibit KIT and PDGFRA kinase signaling through a dual mechanism of action. Enzymological and GIST cell line studies have shown that repetinibcan inhibit multiple primary and secondary resistance mutants of KIT and PDGFRA. To evaluate the efficacy and safety of repetinib as a fourth or second-line treatment option for patients with advanced gastrointestinal stromal tumors, an international pivotal Phase III in vivo study was conducted. Preliminary analysis by INVICTUS showed that repetitinib achieved significantly longer progression-free survival (PFS) compared with placebo, at 6.3 months. In addition, repetinib provided a clinically meaningful improvement in overall survival of 18.2 months and an objective response rate (ORR) of 11.8%.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. Repetinib’s drug donation policy requires patients to learn about it through relevant institutions, which will reduce the price to reduce the burden on patients and increase the progress of drug treatment. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.